My name is Elena Sukhacheva. I am director of Medical and Scientific Affairs and based in Nyon in Switzerland, working for Beckman Coulter. Currently, we are working with the clinical adoption of new sepsis biomarker, MDW, which has been recently approved by FDA for the sepsis detection in the ED, and also it has been CE marked for the COVID-19.
So we are putting our scientific effort to make this biomarker adopted by the clinicians in the Europe, in the U.S., and in other countries to help with early sepsis detections. It's critically important to detect sepsis as early as patient comes to the hospital, and the problem of early sepsis detection is that sepsis, this is not single diagnosis.
Sepsis may present in million of different ways and it's not always can be recognized by the clinicians. So early detection is the key for the effective treatment and for the successful patient recovery. This is why we are working a lot with MDW which is available very early in the patient assessment pathway and may help to identify sepsis even in those patients where it's not suspected by the physician.
You may know that during the last 20 years, there were thousands of publications about new sepsis biomarkers, and the number of the new biomarkers increasing and increasing, but only few of them really finding their place in the clinical practice because, for sepsis, you need biomarker with very good sensitivity and specificity, and it should be more or less not expensive and available for majority of the patients, and not many biomarkers which can have all those features.
I'm quite sure that there is no single best sepsis biomarker. And future of the sepsis detection, this is kind of combining not only biomarkers but also clinical information, what we have for the patient in the hospital, and building algorithms, multivariate algorithms which can be very helpful and especially helpful, as I said, at the beginning of the patient entry into the hospital.
So, and I'm quite sure that in the near future, we will see very powerful algorithms which are able to identify those patients who need further differential diagnosis for the sepsis-related tests.